Abstract
The review presents the features of immunopathogenesis in a new coronavirus infection (COVID-19) and the possibility of correcting the state of the immune system of the patients with the help of a modern domestic synthetic immunomodulator azoximer bromide (Polyoxidonium®). The results of large-scale studies with the inclusion of the drug in the schemes of complex pathogenetic treatment of COVID-19 and immunorehabilitation in post-COVID-19 syndrome (PCS), as well as the possibility of its use for the prevention of acute respiratory infections and COVID-19 in persons with a high risk of infection are considered. High efficacy and safety of azoximer bromide in normalization of the condition in patients, even with severe complicated forms requiring hospitalization in intensive care units (ICU), in reducing the incidence of complications, acute symptoms in post-COVID-19 syndrome, as well as preventing the spread of SARS-CoV-2 virus in the population and the development of symptoms of a new coronavirus infection during prophylactic administration of the drug have been shown. Key words: COVID-19 immunopathogenesis, COVID-19 immunocorrection, azoximer bromide (Polyoxidonium®)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
